CHA Biotech Co. Ltd
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising f… Read more
CHA Biotech Co. Ltd (085660) - Net Assets
Latest net assets as of September 2025: ₩760.33 Billion KRW
Based on the latest financial reports, CHA Biotech Co. Ltd (085660) has net assets worth ₩760.33 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩2.33 Trillion) and total liabilities (₩1.57 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩760.33 Billion |
| % of Total Assets | 32.64% |
| Annual Growth Rate | 7.97% |
| 5-Year Change | -19.83% |
| 10-Year Change | -1.87% |
| Growth Volatility | 45.44 |
CHA Biotech Co. Ltd - Net Assets Trend (2008–2024)
This chart illustrates how CHA Biotech Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CHA Biotech Co. Ltd (2008–2024)
The table below shows the annual net assets of CHA Biotech Co. Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩284.69 Billion | -56.62% |
| 2023-12-31 | ₩656.33 Billion | +124.98% |
| 2022-12-31 | ₩291.73 Billion | -36.03% |
| 2021-12-31 | ₩456.06 Billion | +28.43% |
| 2020-12-31 | ₩355.09 Billion | -5.86% |
| 2019-12-31 | ₩377.18 Billion | +15.35% |
| 2018-12-31 | ₩326.99 Billion | +41.71% |
| 2017-12-31 | ₩230.74 Billion | -19.41% |
| 2016-12-31 | ₩286.32 Billion | -1.30% |
| 2015-12-31 | ₩290.10 Billion | -33.68% |
| 2014-12-31 | ₩437.45 Billion | -14.62% |
| 2013-12-31 | ₩512.34 Billion | +54.59% |
| 2012-12-31 | ₩331.41 Billion | +16.10% |
| 2011-12-31 | ₩285.46 Billion | +80.40% |
| 2010-12-31 | ₩158.24 Billion | +25.98% |
| 2009-12-31 | ₩125.61 Billion | +50.59% |
| 2008-12-31 | ₩83.41 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to CHA Biotech Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3349.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩20.72 Billion | 7.28% |
| Common Stock | ₩28.16 Billion | 9.89% |
| Other Components | ₩235.81 Billion | 82.83% |
| Total Equity | ₩284.69 Billion | 100.00% |
CHA Biotech Co. Ltd Competitors by Market Cap
The table below lists competitors of CHA Biotech Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TV Asahi Holdings Corporation
PINK:THDDY
|
$687.80 Million |
|
Keboda Technology Co Ltd
SHG:603786
|
$688.07 Million |
|
PT Indosat Tbk
PINK:PTITF
|
$688.11 Million |
|
Fujian Longxi Bearing Group Co Ltd
SHG:600592
|
$688.19 Million |
|
Hefei Urban Construction Development Co Ltd
SHE:002208
|
$687.38 Million |
|
MONGOLIAN MINING CRP.REGS
F:29X2
|
$687.32 Million |
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
$687.18 Million |
|
SANGETSU CO LTD
OTCGREY:SGSUF
|
$687.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CHA Biotech Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 281,347,053,080 to 284,688,978,290, a change of 3,341,925,210 (1.2%).
- Net loss of 8,053,908,980 reduced equity.
- Share repurchases of 146,784,720 reduced equity.
- New share issuances of 44,344,981,880 increased equity.
- Other factors decreased equity by 32,802,362,970.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-8.05 Billion | -2.83% |
| Share Repurchases | ₩146.78 Million | -0.05% |
| Share Issuances | ₩44.34 Billion | +15.58% |
| Other Changes | ₩-32.80 Billion | -11.52% |
| Total Change | ₩- | 1.19% |
Book Value vs Market Value Analysis
This analysis compares CHA Biotech Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.32x to 4.09x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩5784.92 | ₩19200.00 | x |
| 2017-12-31 | ₩4599.52 | ₩19200.00 | x |
| 2018-12-31 | ₩6231.05 | ₩19200.00 | x |
| 2019-12-31 | ₩7187.10 | ₩19200.00 | x |
| 2020-12-31 | ₩6757.39 | ₩19200.00 | x |
| 2021-12-31 | ₩8106.14 | ₩19200.00 | x |
| 2022-12-31 | ₩5184.66 | ₩19200.00 | x |
| 2023-12-31 | ₩4996.00 | ₩19200.00 | x |
| 2024-12-31 | ₩4695.25 | ₩19200.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CHA Biotech Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.77%
- • Asset Turnover: 0.48x
- • Equity Multiplier: 7.71x
- Recent ROE (-2.83%) is below the historical average (-0.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 5.35% | 6.26% | 0.69x | 1.25x | ₩-3.88 Billion |
| 2009 | 4.37% | 1.51% | 1.57x | 1.83x | ₩-7.02 Billion |
| 2010 | 3.23% | 1.34% | 1.14x | 2.11x | ₩-10.72 Billion |
| 2011 | 1.41% | 1.19% | 0.71x | 1.67x | ₩-24.43 Billion |
| 2012 | 7.94% | 5.30% | 0.89x | 1.68x | ₩-6.33 Billion |
| 2013 | 6.63% | 4.82% | 0.77x | 1.79x | ₩-12.93 Billion |
| 2014 | 0.96% | 0.83% | 0.56x | 2.09x | ₩-26.87 Billion |
| 2015 | -5.16% | -3.80% | 0.61x | 2.22x | ₩-43.97 Billion |
| 2016 | 5.90% | 3.76% | 0.58x | 2.69x | ₩-11.75 Billion |
| 2017 | -20.15% | -11.14% | 0.53x | 3.44x | ₩-69.58 Billion |
| 2018 | 7.46% | 4.99% | 0.52x | 2.90x | ₩-8.31 Billion |
| 2019 | 12.29% | 8.67% | 0.46x | 3.08x | ₩8.66 Billion |
| 2020 | -5.25% | -2.81% | 0.51x | 3.70x | ₩-54.17 Billion |
| 2021 | -3.06% | -1.92% | 0.47x | 3.37x | ₩-59.57 Billion |
| 2022 | -16.30% | -5.63% | 0.53x | 5.51x | ₩-76.72 Billion |
| 2023 | -3.00% | -0.88% | 0.55x | 6.13x | ₩-36.57 Billion |
| 2024 | -2.83% | -0.77% | 0.48x | 7.71x | ₩-36.52 Billion |
Industry Comparison
This section compares CHA Biotech Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CHA Biotech Co. Ltd (085660) | ₩760.33 Billion | 5.35% | 2.06x | $687.43 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |